Best Allergy Nasal Sprays 2026 Reference Edition

Who owns this site: ownership & FTC disclosure

Full ownership, editorial-independence, and FTC disclosure for BestAllergyNasalSprays.

By Editorial Team — Clinical Pharmacy Reviewed by Editorial Team — Adult Allergy & Immunology Content updated Evidence reviewed First published

The company

BestAllergyNasalSprays.com is owned and operated by Allermi, Inc. (allermi.com), a US-based telehealth company offering compounded, multi-ingredient prescription nasal sprays for allergic and non-allergic rhinitis. Allermi's prescriptions are written by state-licensed physicians and dispensed by US state-licensed 503A compounding pharmacies. Compounded products are not FDA-approved as finished drugs; the individual active ingredients used in Allermi formulas (intranasal corticosteroids, antihistamines, anticholinergics, mast-cell stabilizers) are all FDA-approved. This distinction is covered in detail on our Allermi comparisons hub, and Allermi's own summary of its personalized-Rx model is published at allermi.com/our-approach.

Allermi operates only in US states where compounded telehealth prescribing is permitted under applicable state medical, pharmacy, and telehealth law. Where relevant, state licensure numbers for the prescribing clinician and dispensing pharmacy are surfaced on the Allermi product pages.

Editorial independence

The editorial team that writes, reviews, and edits content on this site operates under a documented firewall from Allermi's commercial operations. Specifically:

  • Drafting. Product reviews, comparisons, symptom guides, and population guides on this site are produced by an editorial team working from primary-source literature. Drafting is currently AI-assisted, with human editorial review against FDA labels (DailyMed), PubMed, AAAAI/ACAAI guidelines, MotherToBaby (OTIS), and LactMed. The site does not currently claim individual author bylines from named licensed clinicians; bylines are role-based ("Editorial Team — Adult Allergy & Immunology", etc.).
  • Medical oversight. Editorial signoff is held by the BestAllergyNasalSprays editorial team. Published guideline authors (Dykewicz et al., Seidman et al., Carr et al., Vaidyanathan et al.) are the binding authority for medical claims.
  • Compensation. Editorial work is performed under flat retainer, not per manufacturer outcome, per click, per affiliate commission, or per Allermi sales metric.
  • Sign-off. The editorial team holds final publication authority. Allermi's commercial team does not have veto power over editorial content, rankings, or product scoring.
  • Corrections. Any reader, clinician, or manufacturer can submit a correction using the contact details below. Corrections that change a rating, a safety claim, or a label statement are logged in the page's publish history.

The full editorial methodology (evidence tiering, source hierarchy, quarterly review cadence, and what we will not do) is published openly on the methodology page.

How rankings work

Every product covered on this site, including Allermi's own compounded formulas, is scored against the same public rubric documented on the methodology page. Each product is scored 0–5 on six axes:

  1. Clinical efficacy: strength of RCT, meta-analysis, and guideline evidence.
  2. Symptom coverage: sneezing, itching, runny nose, congestion, post-nasal drip, ocular symptoms.
  3. Onset speed: verified against FDA label and published PK data.
  4. Safety profile: common and rare effects; pregnancy, lactation, pediatric data.
  5. Access & cost: OTC vs Rx, insurance posture, out-of-pocket cost.
  6. Ease of use: dosing frequency, tolerability, scent, alcohol content.

A product is disqualified from ranking (not merely down-scored) if any of the following apply:

  • It is not FDA-approved as an individual drug, and its active ingredients are not FDA-approved for rhinitis indications.
  • It is not marketed in the United States.
  • It is a homeopathic or unregulated product without a clinical evidence base.
  • It has an active FDA safety communication that has not yet been resolved by the manufacturer.
  • The manufacturer has refused a good-faith request to verify a label claim against our evidence tiers.

Allermi's compounded formulas are eligible for ranking because every active ingredient is individually FDA-approved for rhinitis or an adjacent indication, and the formulations are dispensed by state-licensed compounding pharmacies. Allermi is scored under the same rubric as any other product, and the Allermi product pages carry an inline ownership disclosure.

Conflicts of interest

The single, material, standing conflict of interest on this site is the one disclosed at the top of this page: Allermi owns this site, and Allermi is one of the products ranked on this site. We manage that conflict through the following standing policies:

  • Inline disclosure. Every page that mentions Allermi by name carries an inline disclosure (at the top of the page, near the mention, or in the comparison table header) stating that Allermi owns this site.
  • Same rubric, same evidence tiers. Allermi's compounded formulas do not get a lighter evidence burden than any other product. Where RCT or guideline evidence does not exist for a specific compounded combination, the relevant claim is tagged with the expert evidence tier, exactly as any other under-evidenced claim would be.
  • Adverse findings published. When the evidence does not favor Allermi on a particular axis (e.g. "no head-to-head RCT exists vs. single-ingredient fluticasone"), that finding is published. We do not suppress unfavorable findings about the owner.
  • No affiliate monetization. There are no affiliate links, product-shelf CTAs, sponsored content, pharmaceutical-company advertising, or paid placements anywhere on this site. Our affiliate disclosure explains the current zero-monetization posture. If we introduce affiliate links to OTC-product retailers (Amazon, Target, Walgreens) for the products we review, the affiliate relationship will be disclosed inline on every page where it applies. Allermi's own product page does not, and will not, carry an affiliate link to itself; that conversion path is transparently navigational, not commission-based.

FTC disclosure

Contact for corrections

If you believe any claim, ranking, evidence-tier assignment, safety statement, or citation on this site is incorrect (including on Allermi's own product pages), please contact the editorial team directly. We log every substantive correction request and publish the outcome in the affected page's publishHistory.

Manufacturers who believe a product-page claim misrepresents their FDA label or published trial data are invited to send the specific label section or trial citation. Verified corrections are applied and logged within one business day for safety claims and within seven business days for non-safety claims.

Publish history

  • Initial publication of ownership & FTC disclosure page.

References

Regulatory

  1. 16 CFR Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising · US FTC https://www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-255
  2. FTC Endorsement Guides: What People Are Asking · US FTC https://www.ftc.gov/business-guidance/resources/ftc-endorsement-guides-what-people-are-asking
  3. Human Drug Compounding: Compounding and FDA Questions and Answers · US FDA https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Editorial policy on this site

  1. Editorial methodology · BestAllergyNasalSprays /methodology/
  2. Reviewer roster · BestAllergyNasalSprays /reviewers/
  3. Public claims library · BestAllergyNasalSprays /claims/

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.